{"id":"W4283709628","doi":"10.1136/annrheumdis-2022-eular.1268","title":"POS0643 SUSTAINABILITY OF RESPONSE BETWEEN UPADACITINIB AND ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS THROUGH 3 YEARS FROM THE SELECT-COMPARE TRIAL","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health; Odense Universitetshospital; Amgen; National Institute of Allergy and Infectious Diseases; Bristol-Myers Squibb","keywords":"Medicine; Adalimumab; Rheumatoid arthritis; Internal medicine; Discontinuation; Placebo; Methotrexate; Post-hoc analysis; Clinical trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004069136,0.001292715,0.0034725,0.00029821,0.0005775305,0.002019847,0.0005762132,0.001504802,0.004417974],"category_scores_gemma":[0.003465567,0.0004454162,0.005194065,0.0005606058,0.001280233,0.002560028,0.0008962631,0.004045164,0.001101297],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001050585,"about_ca_system_score_gemma":0.001022288,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007968502,"about_ca_topic_score_gemma":0.001760184,"domain_scores_codex":[0.9978993,0.0009846253,0.0001773388,0.0003317893,0.0002054994,0.0004014314],"domain_scores_gemma":[0.9973909,0.0007572449,0.0007714393,0.0003135783,0.0001904731,0.0005764041],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9378965,0.002316878,0.009369787,0.0007819526,0.006547584,0.00007336324,0.0001336826,0.001245615,0.001672183,0.0003158831,0.002180542,0.03746598],"study_design_scores_gemma":[0.608718,0.2548464,0.1108803,0.0004028108,0.01243285,0.000417411,0.0004731192,0.002046391,0.001888229,0.001373186,0.006344405,0.0001769519],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871452,0.007307114,0.0002973001,0.0007167818,0.0003826599,0.0002424448,0.00180681,0.00005673991,0.00204503],"genre_scores_gemma":[0.9941311,0.001254029,0.0002300336,0.0007632381,0.0003705135,0.0002644963,0.001981711,0.00001929782,0.0009855623],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004417974,"threshold_uncertainty_score":0.0215199,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02712574030222329,"score_gpt":0.3076212486889632,"score_spread":0.2804955083867399,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}